BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VQPH) today announced the publication of preclinical data demonstrating that the company’s lead product candidate, VQD-002 (triciribine phosphate monohydrate or TCN-P), disrupts a specific signaling pathway associated with chemoresistance and cancer cell survival in ovarian cancer. The study results, published in the current issue of the peer-reviewed publication Cancer Research, indicate that VQD-002 could play a role in reversing drug resistance in ovarian cancer for patients treated with chemotherapy in the years ahead.
